Genetic Testing in Evaluating Risk of Anthracycline Cardiomyopathy: Are We There Yet?
JACC CardioOncol
.
2023 May 2;5(3):406-408.
doi: 10.1016/j.jaccao.2023.02.003.
eCollection 2023 Jun.
Authors
Jeannette R Wong-Siegel
1
,
Yuri Kim
2
,
Nathan O Stitziel
3
4
5
,
Ali Javaheri
2
Affiliations
1
Washington University School of Medicine, Department of Pediatrics, St. Louis, Missouri, USA.
2
Brigham and Women's Hospital, Cardiovascular Division, Boston, Massachusetts, USA.
3
Washington University School of Medicine, Department of Medicine, St. Louis, Missouri, USA.
4
McDonnell Genome Institute, Washington University School of Medicine, St. Louis, Missouri, USA.
5
Washington University School of Medicine, Department of Genetics, St. Louis, Missouri, USA.
PMID:
37397085
PMCID:
PMC10308055
DOI:
10.1016/j.jaccao.2023.02.003
No abstract available
Keywords:
chemotherapy; genomics; heart failure; pediatric cancer; prediction.
Publication types
Editorial